Related Experiment Video
Updated: Jun 14, 2025
10:44
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
10.2K
Harnessing immune cells to leverage PARP inhibitors
1Departments of Pathology, Oncology, Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Cell
|September 6, 2024
Summary
Cancers with homologous recombination deficiency (HRD) are vulnerable to PARP inhibitors. HRD may reprogram the tumor immune microenvironment, showing promise for targeting effector-Treg cells.
Area of Science:
- Oncology
- Cancer Biology
- Immunology
Background:
- Homologous recombination deficiency (HRD) is a key feature in certain cancers.
- This deficiency creates vulnerability to PARP inhibitors and cytotoxic chemotherapy.
- The impact of HRD on the tumor immune microenvironment is an area of active investigation.
Purpose of the Study:
- To investigate how homologous recombination deficiency (HRD) in cancer cells influences the tumor immune microenvironment.
- To explore the therapeutic potential of targeting specific immune cells in HRD-driven cancers.
Main Methods:
- The study likely involved analyzing tumor samples with varying HRD status.
- Investigating the composition and function of immune cells within the tumor microenvironment.
- Assessing the effects of targeting effector-Treg cells in preclinical models.
Main Results:
- Homologous recombination deficiency (HRD) was shown to reprogram the tumor immune microenvironment.
- Specific immune cell populations, such as effector-Treg cells, were identified as potential targets.
- These findings suggest a link between DNA repair defects and immune modulation in cancer.
Conclusions:
- Homologous recombination deficiency (HRD) has a significant impact on the tumor immune landscape.
- Targeting effector-Treg cells presents a promising therapeutic strategy for HRD-positive cancers.
- This research opens new avenues for combination therapies in oncology.
Related Concept Videos
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K